Choong-Hwan Lee, Ph.D., is the co-founder, interim CEO, CFO & COO of Biorevert Inc. He gladly joined a new entrepreneurial journey to achieve professor Cho's conceptual idea about reverting cancer cells to normal which was, for him, thought to be a loonshot at first. He believes that biotech and bio-industries in Korea are now on the verge of the Big bang just as the mobile phone and internet businesses he experienced 20 years ago. Prior, he, fortunately, had various opportunities for entrepreneurship in those fields of business with his academic background in computer vision and graphics, especially face recognition and large-scale medical image data visualization. During his entrepreneurship, he experienced the entire life-cycle of a tech startup company from initial idea to IPO, M&A, and restructuring. As a successful entrepreneur, he later couched and taught young students or future entrepreneurs at ISK (Institute for Startup KAIST) and K-School (one-year entrepreneur graduate degree program) for about 6 years.
He loves walking with his dog, swimming, and hitting balls with friends and family. All leads to reaching enlightenment of life.
Kwang-Hyun Cho, PhD
Kwang-Hyun Cho, Ph.D., is the co-founder & chief scientific officer (CSO) of Biorevert Inc. He has pioneered systems biology in 1999 by his own idea of combining control engineering and biology, and published over 200 research papers in high-profile international journals. He has been a professor in electrical engineering (1999-2003) and medicine (2004-2007). He is currently a professor in the department of Bio and Brain Engineering at KAIST (Korea Advanced Institute of Science and Technology) and the director of Laboratory for Systems Biology and Bio-inspired Engineering, KAIST (https://sbie.kaist.ac.kr/). He came up with the concept of reversion therapy on the basis of his systems biological research and co-founded Biorevert to achieve this conceptual goal in humans. He leads the science of Biorevert.
He likes reading, painting, and walking. The concept of reversion therapy and foundation of Biorevert Inc. are his brain-children obtained during his walk.
Jae Il Joo, PhD
Jae Il Joo, Ph.D., is the co-founder and chief technology officer (CTO) of Biorevert Inc. He manages to further develop the MObyDiCK platform and drug development pipelines at Biorevert. He double majored in biology and computer science in college, so it was natural to be interested in systems biology for his doctoral degree. Jae Il studied Boolean models of cancer complex networks and found that disrupted characteristics of intracellular complex network in cancer can be restored by manipulating specific target genes identified by appropriate network control strategies.
Jae Il enjoys playing video games with his wife in his spare time. Before the COVID-19 pandemic, he also enjoyed sport climbing as his hobby.
Sea Choi, PhD
Sea Rom Choi, Ph.D., is the co-founder & chief global strategist (CGS) of Biorevert Inc. She oversees Biorevert’s clinical and systems biological efforts to bring innovative and effective reversion therapies to patients through unraveling mechanisms of cancer and aging. Prior to founding Biorevert, she mainly focused on studying breast cancer and its relative signaling pathways to systematically identify potential targets to revert malignant breast cancer cells into therapeutically curable breast cancer subtype called luminal-A breast cancer.
To relax, Sea loves watching movies while having seasoned French fries. She is not sure whether it’s movie or French fries that she enjoys more, but she likes both.
Scientific Advisory Board
Anti-cancer drug development
CEO of Oscotec Inc.
Professor, Samsung Hospital
Professor of Graduate School of Medical Science and Technology, KAIST
Small molecule synthesis
Professor of Department of Chemistry, KAIST